TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE

替莫唑胺治疗首次复发的间变性星形细胞瘤

• 批准号: 6244018
• 负责人: STEVEN S ROSENFELD
• 金额: $ 2.46万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-10 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244018
• 关键词: antineoplastics; astrocytoma; clinical research; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; pharmacokinetics; procarbazine

There is currently no standard therapy for patients with cerebral anaplastic gliomas whose tumors recur following surgery, radiotherapy, and adjuvant nitrosourea chemotherapy. Temozolomide (SCH 52365) is related to dacarbazine and is believed to exert cytotoxicity by alkylation of guanine reesidues. Temozolomide has shown possible antitumor activity against gliomas in pilot studies. The present study is a phase II multicenter trial to determine the antitumor activity of temozolomide for patients with cerebral anaplastic astrocytomas at first relapse.

目前，对于脑卒中患者没有标准治疗方法。 间变性胶质瘤，其肿瘤在手术，放疗， 和辅助亚硝基脲化疗。 替莫唑胺（SCH 52365）是 与达卡巴嗪相关，并被认为通过 鸟嘌呤残基的烷基化。替莫唑胺已经显示出 在先导性研究中对神经胶质瘤的抗肿瘤活性。 本研究 是一项II期多中心试验，以确定 替莫唑胺首次用于脑间变性星形细胞瘤患者 复发